Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline Cambridge (UK) based Mission Therapeutics, a clinical-stage biotechnology company developing novel therapeutics that promote the removal of dysfunctional mitochondria to restore cellular health and function, announced the divestment of MTX652, […]
The World Cup kicked off this week and so did our clients, with new appointments, important clinical trial updates and major collaborations announced! The Optimum team was proud to support and attend Weatherden’s Symposium on Women’s Health yesterday, which featured a stellar line-up of speakers to explore how smarter clinical development and regulatory strategy can […]
The heatwave has been replaced by heavy showers, but June is looking bright for our clients, with huge congratulations to Ona Therapeutics for its $86.6M Series B financing and to DaltonTx for the launch of its AI-enabled drug discovery platform. Dr. Hans Eriksson is joining FundaMental Pharma’s team as CMO and Renée Aguiar-Lucander participated in […]
Weekly roundup: May the ‘4th’ be with you! May the ‘4th’ be with you! (Sorry – we couldn’t help ourselves.) The force of innovation was strong across the life sciences sector this week. The Optimum team joined leaders from across the industry at this year’s BioEquity Europe conference in Prague, where discussions reflected the sector’s […]
Easter may be over, but momentum across life sciences is building. Anglonordic Life Science Conference is less than two weeks away, alongside a steady stream of clinical progress, partnerships, and industry milestones, it’s all go! Our latest Optimum TV episode features Stephen Hansen of BioCentury and offers fresh insights into market trends and the Q2 […]
